Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia-Reference-Cited by-同舟云学术

Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia

Published:2020-12-16 Issue:1 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Das Shampa¹^ORCID,Fitzgerald Richard²,Ullah Asad²,Bula Marcin²,Collins Andrea M.²³,Mitsi Elena³,Reine Jesus³,Hill Helen³,Rylance Jamie²³,Ferreira Daniela M.³,Tripp Karen²,Bertasini Andrea⁴,Franzoni Samantha⁴,Massimiliano Mameli⁴,Lahlou Omar⁵,Motta Paola⁵,Barth Philip⁵,Velicitat Patrick⁵,Knechtle Philipp⁵^ORCID,Hope William¹²^ORCID

Affiliation:

1. Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom

2. Liverpool University Hospital Foundation Trust, Liverpool Health Partners, Liverpool, United Kingdom

3. Liverpool School of Tropical Medicine, Liverpool Health Partners, Liverpool, United Kingdom

4. Aptuit (Verona) Srl, an Evotec Company, Verona, Italy

5. Allecra Therapeutics SAS, St-Louis, France

Abstract

Cefepime-enmetazobactam is a novel β-lactam–β-lactamase inhibitor combination with broad-spectrum antimicrobial activity against a range of multidrug-resistant Enterobacteriaceae . This agent is being developed for a range of serious hospital infections. An understanding of the extent of partitioning of β-lactam–β-lactamase inhibitor combinations into the human lung is required to better understand the potential role of cefepime-enmetazobactam for the treatment of nosocomial pneumonia.

Funder

Allecra Therapeutics

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01468-20

Reference23 articles.

1. Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β-Lactam−β-Lactamase Inhibitor Combination

2. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria

3. In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014–2015